Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. - Cortes, Jorge E.; Roboz, Gail J.; Baer, Maria R.; Jonas, Brian A.; Schiller, Gary J.; Yee, Karen; Ferrell, P. Brent; Yang, Jay; Wang, Eunice S.; Blum, William G.; Mims, Alice; Tian, Hua; et al. (Journal of Hematology & Oncology, 2025)